CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Donidalorsendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04307381
NCT04307381Phase 2Completed
CompareCT.gov

An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema

Ionis Pharmaceuticals, Inc.·interventional·Posted Mar 13, 2020·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating Donidalorsen for Hereditary Angioedema. Completed, enrolled 20 participants across 7 sites in 2 countries.

Detailed Summary

The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema
CountriesNetherlands, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 13, 2020
Enrollment StartMar 31, 2020
Primary CompletionJan 24, 2025
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.3 years ago

Interventions

Donidalorsendrug

Donidalorsen administered SC